769 completed, 362 unknown, 260 recruiting, 240 terminated. 1189 Phase 2, 462 Phase 3, 411 Phase 1, 47 Not applicable, 35 Phase 4.
Follow Capecitabine: new trials by email Literature Review of Capecitabine trials Research Report on Capecitabine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal Adenocarcinoma ONO-4578, Placebo, Nivolumab - Gastric Cancer, Esophagogastric Junction Cancer | Phase 3 | Not yet recruiting | Ono Pharmaceutical Co., Ltd. | 600 | 2027-02-01 | 2026-09-14 |
| Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract Cancer Futibatinib, Ivosidenib + Capecitabine, Zanidatamab + Capecitabine - Biliary Tract Cancer (BTC) | Phase 3 | Not yet recruiting | UNICANCER | 990 | 2027-01-02 | 2026-08-04 |
| Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Trial Short-course radiotherapy, CAPOX (oxaliplatin/capecitabine), Sintilimab - Local Advanced Rectal Cancer, PD-1 Inhibitor | Phase 3 | Not yet recruiting | Guangdong Provincial People's Hospital | 148 | 2027-01-01 | 2026-07-07 |
| Feasibility Study of Huangqi Yangyuan Formula for Capecitabine-Induced Adverse Reactions in Advanced Colorectal Cancer Capecitabine, Huangqi Yangyuan Formula (Chinese Herbal Decoction) - Advanced Colorectal Cancer, Capecitabine-Related Adverse Reaction | Not applicable | Not yet recruiting | Huanfang Fan | 35 | 2027-01-01 | 2026-11-03 |
| Dynamic Plasma EBV DNA-Guided Risk-Adapted Treatment With Becotatug Vedotin (MRG003) Plus PD-1 Blockade in Locoregionally Advanced Nasopharyngeal Carcinoma Becotatug Vedotin, Pucotenlimab, Intensity-Modulated Radiotherapy - Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer | Phase 2 | Not yet recruiting | Sun Yat-sen University | 298 | 2026-12-01 | 2026-10-27 |
| Risk-Adapted Anlotinib and PD-L1 for Locoregionally Advanced Nasopharyngeal Carcinoma Anlotinib Hydrochloride Capsules, Benmelstobart, Gemcitabine (GEM) - Nasopharyngeal Cancinoma (NPC) | Phase 2 | Not yet recruiting | Sun Yat-sen University | 214 | 2026-12-01 | 2026-10-29 |
| A Study of Zolbetuximab Given With mFOLFOX6 or CAPOX Chemotherapy in Indian Adults With Gastric Cancer Zolbetuximab, Oxaliplatin, Folinic Acid - Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Phase 4 | Not yet recruiting | Astellas Pharma Global Development, Inc. | 50 | 2026-11-30 | 2026-09-21 |
| Zanidatamab Combined With Liposomal Irinotecan and Capecitabine for Second-line Treatment of HER2-positive Unresectable Biliary Tract Tumors Zanidatamab - Biliary Tract Cancer | Phase 2 | Not yet recruiting | Anhui Provincial Hospital | 15 | 2026-11-30 | 2026-10-01 |
| Hepatic Arterial Infusion Chemotherapy Versus Capecitabine as Adjuvant Therapy for Resected Biliary Tract Cancer Oxaliplatin, 5-Fluorouracil, Capecitabine - Biliary Tract Cancer, Cholangiocarcinoma | Phase 3 | Not yet recruiting | Zhai Wenlong | 90 | 2026-11-30 | 2026-11-04 |
| Sintilimab Combined With LCCRT Followed by Capeox Chemotherapy in pMMR/MSS/MSI-L Locally Advanced Rectal Cancer Oxaliplatin, Placebo, radiotherapy - Locally Advanced Rectal Cancer | Phase 3 | Not yet recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 500 | 2026-11-25 | 2026-11-04 |
| A Study of BON-C1393 in Adults With Advanced Solid Tumors BON-C1393, Bevacizumab, Capecitabine - Solid Tumors, Advanced Solid Tumors | Phase 1 | Not yet recruiting | BeOne Medicines | 90 | 2026-11-23 | 2026-10-29 |
| SCRT Combined With CAPOX and PD-1 Antibody Versus LCRT Combined With CAPOX for Early Low-lying Rectal Cancer (TORCH-E3) Short-course radiotherapy, Long-course radiation, PD-1 antibody (Sintilimab) - Early Low Rectal Cancer | Phase 3 | Not yet recruiting | Fudan University | 394 | 2026-11-15 | 2026-11-12 |
| A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From India With Different Types of Cancer (MK-3475-G44/KEYNOTE-G44) Pembrolizumab, Cisplatin, 5-Fluorouracil - Neoplasm Malignant, Gastric Neoplasms | Phase 4 | Not yet recruiting | Merck Sharp & Dohme LLC | 150 | 2026-11-06 | 2026-09-03 |
| A Prospective, Biomarker-Stratified Phase 2 Study: β-Hydroxybutyrate as a Predictive Biomarker for Short-Course Radiotherapy Followed by Chemotherapy Plus PD-1 Inhibitor Versus Chemotherapy Alone in Locally Advanced Rectal Cancer Short-course radiotherapy, Capecitabine, Oxaliplatin - Rectal Cancer, Radiotherapy | Phase 2 | Not yet recruiting | Tao Zhang | 144 | 2026-11-01 | 2026-10-06 |
| Combining DCSZ11 With Radiation and Chemotherapy as Neoadjuvant Treatment for pMMR Locally Advanced Rectal Cancer DCSZ11, Radiation, Capecitabine - Rectal Cancer | Phase 2 | Not yet recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 30 | 2026-11-01 | 2026-10-28 |
| RC118 Combined With RC148 as First-Line Treatment for Claudin 18.2-Positive, HER2-Negative Advanced G/GEJ Adenocarcinoma RC118(Dose 1) plus RC148(Dose 1), RC118(Dose 1) plus RC148(Dose 2), RC118(Dose 2) plus RC148(Dose 1) - Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 2 / Phase 3 | Not yet recruiting | RemeGen Co., Ltd. | 680 | 2026-11-01 | 2026-11-13 |
| A Phase II Study of HLX22 in Combination With Trastuzumab and Chemotherapy in HER2-Positive Locally Advanced or Metastatic Breast Cancer Patients HLX22, Trastuzumab, Capecitabine - HER2 + Breast Cancer | Phase 2 | Not yet recruiting | Shanghai Henlius Biotech | 90 | 2026-10-31 | 2026-09-17 |
| A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055) Sac-TMT, Pembrolizumab and Berahyaluronidase alfa, Cisplatin - Bladder Cancer | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 400 | 2026-10-23 | 2026-11-16 |
| A Multicenter, Randomized, Controlled Phase III Clinical Trial on Adjuvant Intensified Therapy for Patients With Residual Disease After Neoadjuvant Treatment for Triple-negative Breast Cancer Capecitabine and PD-1 inhibitor, PD-1 inhibitor, Capecitabine - Newly Diagnosed Triple-negative Breast Cancer | Phase 3 | Not yet recruiting | Shandong Cancer Hospital and Institute | 852 | 2026-10-17 | 2026-10-09 |
| A Prospective, Single-center, Phase II Study of Neoadjuvant Serplulimab Plus XELOX and Bevacizumab in Locally Advanced Rectal Cancer Serplulimab, Bevacizumab, Oxaliplatin - Locally Advanced Rectal Cancer | Not applicable | Not yet recruiting | Tang-Du Hospital | 48 | 2026-10-15 | 2026-10-13 |
Showing 20 of 1956. Sign in to see all of them.
Breast Neoplasms (409) · Colorectal Neoplasms (322) · Rectal Neoplasms (237) · Stomach Neoplasms (218) · Pancreatic Neoplasms (139) · Neoplasm Metastasis (124) · Colonic Neoplasms (94) · Neoplasms (90) · Triple Negative Breast Neoplasms (67) · Esophageal Neoplasms (57) · Biliary Tract Neoplasms (43) · Nasopharyngeal Carcinoma (36) · Cholangiocarcinoma (35) · Adenocarcinoma (34) · Gallbladder Neoplasms (31)
Hoffmann-La Roche (91) · Fudan University (76) · Sun Yat-sen University (59) · National Cancer Institute (NCI) (37) · M.D. Anderson Cancer Center (30) · Merck Sharp & Dohme LLC (26) · Alliance for Clinical Trials in Oncology (22) · Asan Medical Center (19) · AstraZeneca (19) · ImmunityBio, Inc. (18) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (17) · Chinese Academy of Medical Sciences (16) · UNICANCER (16) · Tianjin Medical University Cancer Institute and Hospital (15) · Pfizer (14)
United States (657) · China (600) · South Korea (173) · France (171) · Spain (166) · Italy (161) · United Kingdom (145) · Germany (141) · Canada (121) · Taiwan (99) · Australia (96) · Japan (88) · Belgium (87) · Brazil (77) · Poland (74)
Yoon-Koo Kang, MD, PhD (7) · Binghe Xu (6) · Christopher H. Crane, MD (6) · Lin Shen, MD (6) · Michele Reni, MD (6) · Norman Wolmark, MD (6)
PMID 34037241, PMID 35623069, PMID 36306483, PMID 15496622, PMID 40341124, PMID 22226517, PMID 39863139, PMID 41121239, PMID 15383798, PMID 17042060, PMID 17175450, PMID 18669454, PMID 19269519, PMID 19906561, PMID 20728210, PMID 21128114, PMID 21596621, PMID 21937232, PMID 22067400, PMID 24472478, PMID 24495589, PMID 26156652, PMID 26187751, PMID 29234923, PMID 29508247, PMID 29804905, PMID 33093337, PMID 33439695, PMID 33792646, PMID 34515993, PMID 36135045, PMID 37037952, PMID 37310167, PMID 37499870, PMID 37957132, PMID 38564700, PMID 39024777, PMID 39047732, PMID 40117530, PMID 40373876, PMID 40657894, PMID 41324998, PMID 42371751, PMID 10623705, PMID 10918161, PMID 10944647, PMID 11248153, PMID 11919232, PMID 11919233, PMID 12065558
2023 (28), 2008 (17), 2018 (16), U10CA032102 (13), 2016 (12), 2025 (12), 2014 (10), 2015 (9), U10CA180820 (9), 2019 (8), 2005 (7), U10CA180868 (7), 2009 (6), 2017 (6), U10CA180821 (5)